Acrivon Therapeutics, Inc. Common StockACRVNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +72.57% | +71.22% | +69.76% | +6.45% | +1.19% |
| Weighted Average Shares Diluted Growth | +72.57% | +71.22% | +69.76% | +6.45% | +1.19% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +42.09% | +42.18% | +46.32% | -31.23% | -32.32% |
| Book Value per Share Growth | -17.41% | -14.81% | -12.50% | -37.81% | -35.45% |
| Debt Growth | -9.21% | -21.51% | -20.94% | -22.70% | -25.52% |
| R&D Expense Growth | +83.73% | +19.56% | +37.03% | +7.70% | -29.24% |
| SG&A Expenses Growth | +6.92% | +13.43% | +0.86% | +0.86% | -3.78% |